Nicolas Emanuel, Bertucci François, Sabatier Renaud, Gonçalves Anthony
Department of Medical Oncology, Institut Paoli-Calmettes, 13009 Marseille, France.
CRCM-Predictive Oncology laboratory, Institut Paoli-Calmettes, Inserm U1068, CNRS UMR7258, Aix-Marseille Univ, 13009 Marseille, France.
Cancers (Basel). 2018 Dec 11;10(12):506. doi: 10.3390/cancers10120506.
Breast cancers (BC) associated with germline mutations of represent 3⁻5% of cases. -associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review, we will summarize clinical trials of chemotherapy and PARP inhibitors (PARPi), alone or in combination, at the early or late stage of -associated BC. We will also present the mechanisms of resistance to PARPi as well as the new therapeutic strategies of association with PARPi. Finally, we will discuss under which conditions the use of DNA damaging agents can be extended to the -wild type population, the ness concept.
与种系突变相关的乳腺癌（BC）占病例的3%-5%。与 相关的BC具有导致基因组不稳定的生物学特征以及对DNA损伤剂（包括聚（ADP-核糖）聚合酶（PARP）和铂类药物）的潜在敏感性。在本综述中，我们将总结在与 相关的BC的早期或晚期单独或联合使用化疗和PARP抑制剂（PARPi）的临床试验。我们还将介绍对PARPi的耐药机制以及与PARPi联合使用的新治疗策略。最后，我们将讨论在何种条件下DNA损伤剂的使用可以扩展到 野生型人群，即 概念。
需注意，原文中存在一些未明确的指代（用 表示），可能会影响译文的完整性和准确性。
